key: cord-0878647-k1g3id6k authors: D’Ambrosio, Roberta; Rizzardini, Giuliano; Puoti, Massimo; Fagiuoli, Stefano; Anolli, Maria Paola; Gabiati, Claudia; D’Amico, Federico; Pasulo, Luisa; Restelli, Umberto; Colombo, Massimo; Lampertico, Pietro title: Implementation of HCV screening in the 1969–1989 birth‐cohort undergoing COVID‐19 vaccination date: 2022-03-12 journal: Liver Int DOI: 10.1111/liv.15216 sha: a992fa0245929cb2567dd156cf6523c6a905a36d doc_id: 878647 cord_uid: k1g3id6k BACKGROUND AND AIM: The World Health Organization (WHO) goal of hepatitis C virus (HCV) elimination by 2030 relies on the scaling‐up of both identification and linkage to care of the infected population, worldwide. In Italy, the estimated burden of HCV carriers who are unaware of their infection amounts to 200 000 persons, a projection that reinforces the need for broadening population access to effective screening programmes. METHODS: A pivotal screening programme targeting subjects born between 1969 and 1989 has been conducted in Lombardy, Northern Italy, where point‐of‐care (POC) testing was offered for free concomitantly to COVID‐19 vaccination. RESULTS: Amongst 7219 subjects born between 1969 and 1989 who underwent HCV screening through POC, 7 (0.10%) subjects tested anti‐HCV positive: 5 (0.07%) had confirmed anti‐HCV positivity (Table 1) and 4 of them (0.05%) were HCV‐RNA positive by standard confirmation tests. CONCLUSIONS: This pivotal study demonstrated the feasibility of a POC‐based anti‐HCV screening programme in young adults undergoing COVID‐19 vaccination. The prevalence of HCV infection in subjects born in the 1969–1989 cohort in Italy seems to be lower than previously estimated. Whether the extension of this programme to subjects born before 1969 could lead to improved screening effectiveness should be a matter of debate. This led all Member States to develop specific Nation Hepatitis Plans to achieve the WHO elimination goal, based on expanding diagnosis, linkage to care and treatment strategies, coupled with a number of interventions for hepatitis prevention. 2 Italy has historically been considered amongst the European Countries with the largest burden of HCV, with an estimated prevalence of 1% rising to 7% in the aged population. 3 At the end of July 2021, over 225 000 people had been already treated with DAAs, 4 whereas at least 280 000 people are unaware of their HCV status and have remained unlinked to care according to estimates from the Italian National Institute of Health. 5 Following the COVID-19 pandemic that slowed down the rates of newly diagnosed cases and treatments, 6 as in 2019 Italy was no longer on the track to achieve the WHO elimination goal. More recently, Centers reorganization following the COVID-19 pandemic has further contributed to slower both diagnostic and treatment programmes in most Italian regions. 7 In 2021, the Italian Government promulgated a decree specifically aimed at implementing HCV screening strategies, through the introduction of a free-of-charge screening programme focused on key populations like people who inject drugs (PWID), inmates and cohorts of the general population born between 1969 and 1989. 8 In fact, such a graduated screening model was previously suggested to be most cost-effective, also when compared to models only directed at at-risk populations or other birth-cohorts. 9 To comply with the national screening plan and reduce the costs of mobilization of the general population to screen, we leveraged the ongoing COVID-19 vaccination programme starting a pivotal study | 1013 D'AMBROSIO et Al. Two different POC tests were used: In Tec Advanced Quality® Rapid HCV Antibody Test and Anti-HCV WB/S/P by Project: both tests are single-use qualitative immunoassays to detect antibodies against HCV in capillary blood from finger-stick. POC-positive subjects were referred to outpatient clinics for confirmatory tests, including peripheral vein blood anti-HCV antibodies and HCV-RNA by standard assays. As a predefined recall policy, patients who did not attend the re-test appointments were contacted directly by phone to solicit and reschedule the confirmatory test. HCV-RNA-positive patients were proposed DAAs. All patients signed a consent information form. Overall, over 50 000 individuals underwent COVID-19 vaccination in the four hubs, and 22 584 (2710-10 484) of them were born between 1969 and 1989; the anti-HCV screening could be proposed to at least 7925 of them (data missing from one vaccination hub), and 7219 subjects agreed to be tested, with an acceptance rate ranging between 63% and 85%. Modalities of screening campaigns in each vaccination Center are reported in Table 1 This pivotal study demonstrated not only the feasibility of a universal HCV screening through POC anti-HCV testing in subjects undergoing COVID-19 vaccination but also showed a lower than previously estimated prevalence of HCV infection in Italian subjects born between 1989 and 1969. To the best of our knowledge, this is the first study specifically aimed at prospectively assessing the prevalence of anti-HCV in an unbiased population, at least in Italy. An unexpected finding of the study was the lower than the previously estimated prevalence of HCV markers in the 1989-1969 birthcohort (0.10% for anti-HCV and 0.05% for HCV-RNA absolute. Third, the study has been conducted in hubs serving two of the largest metropolitan areas in Lombardy, not involving more peripheral areas of the region where the HCV prevalence could be higher. Fourth, the proportion of patients tested in this screening programme represents only 0.23% of the overall resident population aged from 32 to 52 years, which accounts for approximately 3 million people. Finally, current epidemiological estimates of HCV prevalence have been generated from dated, retrospective studies, whose biases are well recognized. Particularly, a significant proportion of HCV-infected people from the 1969-1989 birth-cohort would probably belong to the 'high-risk' population, such as PWID and inmates, who may have lower access to screening programmes. This notwithstanding, we think that the study has several strengths: this is the first HCV screening study to be performed in the context of a vaccination hub, the sample size of the study is significant, the tested population is unselected, and adherence to HCV screening programme was excellent. Study conduct at vaccination hubs was significantly influenced by logistic issues, as each vaccination Center dealt with several hundred or even thousand vaccinees every day (up to 10 000), depending on each hub capability. The anti-HCV screening had to be carried on without any interference with the vaccination programme, which had to be prioritized and remain free from delays due to concomitant testing, either before or after vaccine inoculation. These logistics issues were over- In light of these findings, a question arises as to whether opportunistic screening programmes could be really the best strategy. In fact, limitations of this kind of screening are well recognized, and mainly include logistic and organizational issues finally leading to low adherence and/or suboptimal cost-effectiveness, 18 In Italy, a cost-consequence analysis based on a Markov model was implemented by Marcellusi and colleagues. 23 The authors found that the investment necessary to deliver antiviral therapy to newly diagnosed subjects (through active screening) would be recouped in 4.3 years in terms of costs avoided due to the prevention of disease complications, although the cost of the screening activity was not considered in the model. 23 In conclusion, we run a pivotal study leading to the rapid screen World health organization global health sector strategy on viral hepatitis Declining prevalence and increasing awareness of hepatitis C virus infection in Italy: a population-based survey epatite C cronica. Agenzia Italiana del Farmaco Estimated prevalence of undiagnosed HCV infected individuals in Italy: a mathematical model by route of transmission and fibrosis progression Impact of COVID-19 on global HCV elimination efforts Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: a webbased survey Milestones to reach hepatitis C virus (HCV) elimination in Italy: from free-of-charge screening to regional roadmaps for an HCV-free nation Optimization of hepatitis C virus screening strategies by birth cohort in Italy risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy Declining prevalence and increasing awareness of HCV infection in Italy; a populationbased survey in five metropolitan areas Hepatitis C virus infection in an endemic area of southern Italy14 years later: evidence for a vanishing infection Prevalence of undiagnosed hepatitis C virus infected individuals estimates by regional mathematical-modelling in Italy Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study L'infezione cronica da virus dell' epatite C (HCV) in Lombardia A populationbased screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in The Netherlands Routine screening for hepatitis C in pregnancy is cost effective in a large urban population in Ireland: a retrospective study Cost-effectiveness of mass screening for hepatitis C virus among all inmates in an Irish prison Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis. Appl Health Econ Health Policy The authors thank the Welfare Department of Lombardy Regional Government for supporting this activity.